Did you know that 503B Outsourcing Facilities are tracked under CDER Strategic Area 2 – Drug Quality and Compliance on the CDER Dashboard.
Section III identifies Inspections and Enforcement of Compounders. This CDER Dashboard identifies by fiscal year the number of compounds that recalled products, the number of warning letters issued, the number of state referral letters, the number of injuctions/consent decrees, and the total number of regestered outsoursing facilities. … more
In the first 6-months of 2018, fiftteen 503B Outsourcing Facilities were cited for smoke study issues. Airflow is critical in maintaining sterile conditions, as described in the FDA Guide on Aseptic Processing
In an aseptic process, the drug product, container, and closure are first subjected to sterilization methods separately, as appropriate, and then brought together. … more
On May 29, 2018 FDA posted 9 warning letters to online retailers whose networks offered or introduced into interstate commerce, opioids that are misbranded and unapproved new drugs, in violation of sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act [21 U.S.C.… more
Recently a client contacted Performance Validation requesting assistance with the cycle validation for a dry goods autoclave, which had failed to achieve sterility. A biological indicator included in the validation demonstrated growth on completion of the autoclave cycle.
On review of the dry goods autoclave cycle, Performance Validation (PV), identified the autoclave used a gravity cycle. … more
September 2016, I blogged about the draft FDA Guidance Facility Definition Under Section 503B of the FD&C act. In May 2018, the draft guiance was approved and published in the Federal Register and is available here.
FDA has been asked whether an outsourcing facility can create a separate area within its facility for compounding according to patient specific prescriptions under section 503A, and not follow CGMP requirements in that area.… more
Recently a manufacturer of an OTC product was inspected by FDA (Nov 2017) and the resultant warning letter was posted on the FDA website May 2018. This firm received 3 citations which are summarized below:
Observation 1 – the firm elected to manufacture the OTC product with raw material that had not been tested and released by the quality unit. … more
A pharmaceutical manufacturer in Indiana requested help from Performance Validation (PV) with the commissioning and qualification of a new blister card packaging line for a new product launch, as well as facility and utility modifications to support the new packaging line.… more
Come On Man…
|if you watch ESPN Sports Center you have probably heard the announcers do their Come on Man bit. Well perhaps we should have something similar for the pharmaceutical industry when they do something just plain dumb….
How about a CMO in North Carolina that recently received a FDA warning letter.
Question: Can I use my vendor’s Certificate of Analysis when making a pharmaceutical product or compounding a product as a 503B outsourcing facility? Yes – BUT in accordance with 21 CFR 211.84(d)(1) and (2):
(d) Samples shall be examined and tested as follows:
(1) At least one test shall be conducted to verify the identity of each component of a drug product.… more
A Midwestern pharmaceutical company planned to upgrade their in-process checks for blister card integrity from a destructive blue dye leak test to a non-destructive, vision system-based leak test. The existing blue dye leak test required that all tested blister cards be discarded even if they passed.… more